18F-labeled radiopharmaceuticals for PET in oncology, excluding FDG
- 1 February 2000
- journal article
- review article
- Published by Elsevier BV in Nuclear Medicine and Biology
- Vol. 27 (2), 103-112
- https://doi.org/10.1016/s0969-8051(99)00109-2
Abstract
No abstract availableKeywords
This publication has 81 references indexed in Scilit:
- Peptide radiopharmaceuticals in nuclear medicineEuropean Journal of Nuclear Medicine and Molecular Imaging, 1999
- Assessment of the biodistribution and metabolism of 5-fluorouracil as monitored by 18F PET and 19F MRI: A comparative animal studyNuclear Medicine and Biology, 1996
- Synthesis of 9-[(3-[18F]-fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]-FHPG): A potential imaging agent of viral infection and gene therapy using PETNuclear Medicine and Biology, 1996
- A chelating derivative of α-melanocyte stimulating hormone as a potential imaging agent for malignant melanomaBritish Journal of Cancer, 1990
- A comparative study of the selectivity and efficiency of target tissue uptake of five tritium-labeled androgens in the ratJournal of Steroid Biochemistry, 1990
- Single-Chain Antigen-Binding ProteinsScience, 1988
- N.C.A. 18F‐fluoroacylation via fluorocarboxylic acid estersJournal of Labelled Compounds and Radiopharmaceuticals, 1988
- Both the σ receptor-specific ligand(+)3-PPP and the PCP receptor-specific ligand TCP act in the mouse vas deferens via augmentation of electrically evoked norepinephrine releaseEuropean Journal of Pharmacology, 1987
- A marker for hypoxic cells in tumours with potential clinical applicabilityBritish Journal of Cancer, 1981
- Quantitative measurements of oxygen tension in normal tissues and in the tumours of patients before and after radiotherapyActa Radiologica, 1960